Thus, combining PCSK9 inhibitors with anti-PD-1/PD-L1 immunotherapy may be a new strategy to improve antitumor effects. Research advances Proprotein convertases (PCs) are a unique class of serine ...

Though currently experimental, this mechanism could complement existing PD-1 and PD-L1 checkpoint inhibitors and improve patient outcomes. How Checkpoint Inhibitors Work Checkpoint inhibitors are ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune system to recognize and attack tumors. To get know more ... (Summit Therapeutics) – A new PD-1/PD-L1 ...

Co-author Dr Kenji Chamoto, from Kyoto University, says, "PD-1 inhibition has a 'yin and yang' nature: it activates anti-tumor immunity but at the same time impedes B-cell immunity.

We are excited to explore the potential of our PD-1 inhibitor, tislelizumab, in combination with ANKTIVA,” said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. “I’ve admired Dr.

Mechanism of action. Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the ...

(NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation Provided by ACCESS Newswire May 8, 2025, 12:45:00 PM ...

According to Akeso, the HARMONi-6 trial marks ivonescimab’s third Phase III success in lung cancer and its second head-to-head win over a PD-1 inhibitor.1 Currently, the treatment is approved in China ...